Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah, U.S.A.
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, U.S.A.
Epilepsia. 2017 Jun;58(6):1054-1062. doi: 10.1111/epi.13742. Epub 2017 Apr 12.
Nonadherence to prescribed dosing regimens is a significant problem in the treatment of pediatric and adult chronic epilepsy, and can result in severe consequences to patient outcomes. In this first-of-kind preclinical study, the impact of nonadherence on seizure control was studied by simulating human patterns of nonadherence in an animal epilepsy model.
In study 1, three different patterns of nonadherence were modeled in newly diagnosed epileptic rats treated with carbamazepine: perfect adherence (100% of pellets contained carbamazepine), variable nonadherence (50% of pellets contained carbamazepine with different dosing patterns between animals), and complete nonadherence (0% of pellets contained carbamazepine). In study 2, a cohort of newly diagnosed epileptic rats were subjected to a "drug holiday" nonadherence paradigm, that is, a 2-week on (100%), 2-week off (0%), and 2-week on (100%) carbamazepine paradigm.
In the first experiment, the 100% (0.3 ± 0.2 SD convulsive seizures per day) adherent cohort demonstrated better seizure control than either the 0% (1.1 ± 0.8 SD) or 50% (0.8 ± 0.6 SD) adherent cohorts, which had similar levels of seizure control. In the second study, poor seizure control was exhibited during the second 2 weeks; that is, the drug holiday epoch; however, this did not negatively affect restoration of seizure control upon reinstatement of CBZ.
The results from this pilot investigation suggest that nonadherence to carbamazepine is associated with significant negative but reversible effects on seizure control in an animal model of epilepsy. Furthermore, these results demonstrate that animal studies of nonadherence can yield potentially important and translatable insights into the consequences of nonadherence on seizure control.
在儿童和成人慢性癫痫的治疗中,不遵守规定的剂量方案是一个严重的问题,可能对患者的治疗结果产生严重后果。在这项首例临床前研究中,通过在动物癫痫模型中模拟人类不遵守药物的模式来研究不遵守药物对癫痫控制的影响。
在研究 1 中,对新诊断为癫痫的用卡马西平治疗的大鼠,模拟了三种不同的不遵守药物模式:完全遵守(100%的药丸含有卡马西平)、可变不遵守(50%的药丸含有卡马西平,动物之间的剂量模式不同)和完全不遵守(0%的药丸含有卡马西平)。在研究 2 中,一组新诊断为癫痫的大鼠接受了“药物假期”不遵守药物的范式,即 2 周服用(100%)、2 周停药(0%)和 2 周服用(100%)卡马西平的范式。
在第一个实验中,100%(每天 0.3±0.2 SD 惊厥发作)的遵守药物的队列显示出比 0%(每天 1.1±0.8 SD)或 50%(每天 0.8±0.6 SD)的遵守药物的队列更好的癫痫控制,后两者具有相似的癫痫控制水平。在第二项研究中,在第二个 2 周,即药物假期期间,表现出较差的癫痫控制;然而,这并没有对重新开始服用 CBZ 时癫痫控制的恢复产生负面影响。
这项初步研究的结果表明,在癫痫动物模型中,不遵守卡马西平与癫痫控制的显著负面但可逆转的影响有关。此外,这些结果表明,对不遵守药物的动物研究可以产生潜在的重要且可转化的关于不遵守药物对癫痫控制影响的见解。